Smith, Richard J. H.
Appel, Gerald B.
Blom, Anna M. http://orcid.org/0000-0002-1348-1734
Cook, H. Terence
D’Agati, Vivette D
Fakhouri, Fadi
Fremeaux-Bacchi, Véronique
Józsi, Mihály http://orcid.org/0000-0002-5520-5535
Kavanagh, David
Lambris, John D.
Noris, Marina http://orcid.org/0000-0001-7651-5033
Pickering, Matthew C.
Remuzzi, Giuseppe http://orcid.org/0000-0002-6194-3446
de Córdoba, Santiago Rodriguez
Sethi, Sanjeev http://orcid.org/0000-0002-4536-7709
Van der Vlag, Johan http://orcid.org/0000-0001-7843-5918
Zipfel, Peter F. http://orcid.org/0000-0002-6149-2411
Nester, Carla M.
Article History
First Online: 28 January 2019
Competing interests
: R.J.H.S. declares that he is Director of the Molecular Otolaryngology and Renal Research Laboratories (which provides genetic and functional testing for complement-mediated renal diseases). G.A. declares that he acts as a consultant for Achillion, Alexion, Chemocentryx and Omeros and has received research grants from Achillion and Chemocentryx. H.T.C. declares that he acts as a consultant for Alexion and Achillion. J.L. declares that he is the founder of Amyndas Pharmaceuticals, is named as an inventor on patents or patent applications describing the therapeutic use of complement inhibitors (some of which are being developed by Amyndas Pharmaceuticals) and is the inventor of the compstatin analogue licensed to Apellis Pharmaceuticals termed 4(1MeW)7 W (also known as POT4 and APL1) and pegylated derivatives such as APL2. M.N. declares that he has received honoraria for lecturing and participation in advisory boards from Alexion Pharmaceuticals and has received research grants from Chemocentryx and Omeros. M.C.P. declares that he has received research grants from Achillion, Alexion and Ra Pharma and has acted as a consultant for Achillion, Alexion, Chemocentryx and Ra Pharma. G.R. declares that he acts as a consultant for Alnylam, Boehringer Ingelheim, Handok, Hoffmann–La Roche and Janssen Research and Development (he has not accepted any personal remuneration from Alnylam or Hoffmann–La Roche; this compensation is used to support his research and educational activities). C.M.N. declares that he is Associate Director of the Molecular Otolaryngology and Renal Research Laboratories. All other authors declare no competing interests.